Methods of treating non-small cell lung cancer with anti-pd-1-antibodies
AssigneeTesaro, Inc.
InventorsMartin HUBER, Niranjan YANAMANDRA, Allene DIAZ, Mary Lynne HEDLEY, Julie Ann KRUEGER, Timothy R. CROSSMAN, Hesham A. ABDULLAH
Life of this patent
Estimating the term…
Abstract
The disclosure provides a method of treating non-small cell lung cancer (NSCLC) in a patient previously treated with an immune checkpoint inhibitor by the administration of dostarlimab or a biosimilar thereof.
Claims29
A method of treating non-small cell lung cancer (NSCLC) in a patient previously treated with a combination of (i) an anti-PD-1 antibody or an anti-PDL1 antibody that is not dostarlimab and (ii) one or more chemotherapeutic agents, the method comprising administering a therapeutically effective amount of dostarlimab to the patient, wherein the patient discontinued administration of the immune checkpoint inhibitor prior to beginning administration of dostarlimab.
(canceled)
(canceled)
(canceled)
-27. (canceled)
-37. (canceled)
-40. (canceled)
A method of treating non-small cell lung cancer (NSCLC) in a patient previously treated with a combination of pembrolizumab, and one or more chemotherapeutic agents, the method comprising administering a therapeutically effective amount of dostarlimab, to the patient.
(canceled)
-75. (canceled)
-90. (canceled)
A method of treating non-small cell lung cancer (NSCLC) in a patient previously treated with chemotherapy and radiotherapy comprising administering dostarlimab or a biosimilar thereof 500 mg Q3W.
(canceled)
(canceled)
Dependencies are inferred from the claim text.